Hiral Patel
Family · Lombard, ILNPI 1619553856
Payments from drug & device makers
Across 104 payments — averaging $25.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$468
- AbbVie$449
- AstraZeneca$375
- Preventric Diagnostics, Inc.$188
- Amgen$161
- Xeris Pharmaceuticals, Inc.$142
- plus $903 from 18 others
What the payments were for
- Food & beverage$2,685100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $468 |
| AbbVie | 18 | $449 |
| AstraZeneca | 10 | $375 |
| Preventric Diagnostics, Inc. | 1 | $188 |
| Amgen | 9 | $161 |
| Xeris Pharmaceuticals, Inc. | 4 | $142 |
| Pfizer | 6 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $99 |
| Novartis | 5 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $91 |
| Bayer | 1 | $91 |
| Lilly USA, LLC | 5 | $82 |
| Dexcom, Inc. | 3 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Idorsia Pharmaceuticals US Inc | 2 | $45 |
| GSK | 2 | $41 |
| Boehringer Ingelheim | 1 | $24 |
| Almatica Pharma LLC | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Merck | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,685 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 76 | $84,088 |
| OzempicSemaglutide | 55 | $57,601 |
| TrulicityDulaglutide | 45 | $44,991 |
| FarxigaDapagliflozin Propanediol | 47 | $43,981 |
| JanuviaSitagliptin Phosphate | 47 | $33,960 |
| RybelsusSemaglutide | 16 | $20,360 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $14,859 |
| MyrbetriqMirabegron | 29 | $14,306 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $12,133 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $10,856 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $9,957 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $7,718 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $4,732 |
| Sucralfate | 12 | $3,473 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $2,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $24 | $84,08876 claims |
| Novo NordiskOzempic, Rybelsus | $468 | $77,96171 claims |
| Lilly USA, LLCTrulicity | $82 | $44,99145 claims |
| AstraZenecaFarxiga | $375 | $43,98147 claims |
| MerckJanuvia | $13 | $33,96047 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $41 | $22,09034 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $14,30629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.
Other family in Lombard
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.